These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 19301006)
1. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Musende AG; Eberding A; Wood C; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Guns ET Cancer Chemother Pharmacol; 2009 Nov; 64(6):1085-95. PubMed ID: 19301006 [TBL] [Abstract][Full Text] [Related]
2. A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. Musende AG; Eberding A; Wood CA; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Tomlinson Guns ES Anticancer Drugs; 2012 Jun; 23(5):543-52. PubMed ID: 22481061 [TBL] [Abstract][Full Text] [Related]
3. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217 [TBL] [Abstract][Full Text] [Related]
4. Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts. Low JC; Wasan KM; Fazli L; Eberding A; Adomat H; Guns ES Cancer Chemother Pharmacol; 2007 Nov; 60(6):821-9. PubMed ID: 17294190 [TBL] [Abstract][Full Text] [Related]
5. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905 [TBL] [Abstract][Full Text] [Related]
6. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800 [TBL] [Abstract][Full Text] [Related]
7. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Liu J; Shimizu K; Yu H; Zhang C; Jin F; Kondo R Fitoterapia; 2010 Oct; 81(7):902-5. PubMed ID: 20554003 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Springate CM; Jackson JK; Gleave ME; Burt HM Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591 [TBL] [Abstract][Full Text] [Related]
9. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208 [TBL] [Abstract][Full Text] [Related]
10. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Hahm ER; Arlotti JA; Marynowski SW; Singh SV Clin Cancer Res; 2008 Feb; 14(4):1248-57. PubMed ID: 18281560 [TBL] [Abstract][Full Text] [Related]
11. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707 [TBL] [Abstract][Full Text] [Related]
12. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel. Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259 [TBL] [Abstract][Full Text] [Related]
13. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer. Jiang J; Loganathan J; Eliaz I; Terry C; Sandusky GE; Sliva D Int J Oncol; 2012 May; 40(5):1339-44. PubMed ID: 22293856 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939 [TBL] [Abstract][Full Text] [Related]
15. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Dalrymple SL; Becker RE; Isaacs JT Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719 [TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of the oral platinum analog satraplatin. Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592 [TBL] [Abstract][Full Text] [Related]
17. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873 [TBL] [Abstract][Full Text] [Related]
18. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070 [TBL] [Abstract][Full Text] [Related]
19. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. de Souza PL; Cooper MR; Imondi AR; Myers CE Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685 [TBL] [Abstract][Full Text] [Related]
20. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Reiner T; de las Pozas A; Gomez LA; Perez-Stable C Cancer Lett; 2009 Apr; 276(1):21-31. PubMed ID: 19046802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]